Forensic · CTXR
Citius Pharmaceuticals
Top signals
Shelf Filed Recent
S-3 shelf registration filed in the last 6 months (dilution capacity).
+6
Bear case preview · free
Citius Pharmaceuticals presents a low-risk profile based on SEC filing analysis, with only one material signal triggered: a recent S-3 shelf registration that provides the company substantial dilution capacity for future capital raises. The absence of bankruptcy indicators, restatements, officer departures, or other distress signals suggests the shelf filing reflects standard financing flexibility rather than acute financial stress. Monitor the next 60-90 days for any actual drawdowns against this shelf capacity or announcements regarding capital deployment, which would clarify whether this represents opportunistic fundraising or a response to unexpected cash needs.
↑ That's free. The $9 report goes deeper: every filing cited by accession number, 36-month chronology, what to watch next.
What we checked
✓ Red flags · 36mo
0 8-K events (bankruptcy, delisting, restatement, auditor, officer)
✓ Cyber · 12mo
0 Item 1.05 disclosures + buried-cyber scan
✓ Dilution · 24mo
1 S-3 + 424B5 filing
✓ Buried events
Item 8.01 sections classified for hidden material disclosures
$9
· one-time · emailed in under a minute
The full bear case on CTXR
Plain-English brief. Every signal cited to the exact SEC filing. 36-month chronology. What changes next.
✓ No-signals refund: if the algorithm finds zero red flags on your ticker, reply "refund" and I send the $9 back same day. No questions.
Not ready to buy? Get a free preview by email instead
We'll email you the top 3 signals on CTXR + a discount code for the full report. No subscription, no spam.
Score another ticker
Not investment advice. Every signal grounded in a specific SEC filing. Companies may respond via info@filingfirehose.com.